In this articlePFEMTSRThomas Fuller | SOPA Images | Lightrocket | Getty ImagesA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Pfizer's newest bet on obesity is already showing promise. The company last week said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, that is expected to close at the end of the year. Just a week ...

Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones. ...

9月29日，Metsera(MTSR.US)(已被辉瑞(PFE.US)收购)宣布MET-097i的两项减重IIb期研究(VESPER-1和 VESPER-13)取得了积极结果。MET-097i是一种同类首创的完全偏向、超长效GLP-1受体激动剂(GLP-1- RA)，具有每月注射1次的给药潜力。Metsera认为，MET-097i可以在稳态下与15mg替尔泊肽的性能相匹 敌或超过，并计划在年底之前启动III期临床试验。 ...

Metsera said on Monday that its experimental obesity drug showed significant weight loss and favorable tolerability in mid-stage studies. ...

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatment retention in both VESPER-1 and VESPER-3 trials Data support Phase 3 initiation in late 2025 NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of VESPER-3 – two Phas ...

Leerink downgraded Metsera (MTSR) to Market Perform from Outperform with a price target of $57, down from $77, after Pfizer (PFE) announced an agreement to acquire Metsera for $4.9B upfront and total potential deal value of about $7.3B contingent on hitting various pipeline-related targets. Metsera’s novel obesity pipeline should help drive Pfizer revenue growth beyond 2028, says the analyst, who believes Metsera’s assets could collectively generate greater than $5B in peak sales. Elevate Your Investing S ...

Making a major move in the obesity drug market, Pfizer (PFE)  announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR)  by the end of the year for $4.9 billion or $47.50 a share.The deal has a potential value of up to $7.3 billion when including milestone-based payments of up to $22.50 per share, which would bring the total acquisition stock price for MTSR up to $70.In the wake of the news, Metsera stock has surged +60% to over $50, with the price performance of Pfizer shares being vir ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Metsera, Inc. (NASDAQ: MTSR) related to its sale to Pfizer Inc. Under the terms of the pr ...

We recently published 10 Stocks Stealing Wall Street’s Spotlight. Metsera Inc. (NASDAQ:MTSR) is one of the top performers on Monday. Shares of Metsera Inc. (NASDAQ:MTSR) jumped to a new all-time high on Monday, as investors gobbled up shares following news that it was set to be acquired by Pfizer Inc. (NYSE: PFE) for a potential transaction value of more than $7 billion. During the session, Metsera Inc. (NASDAQ:MTSR) soared to its highest price of $54.46 before trimming gains to close the day just up by ...

Key Takeaways Pfizer will buy Metsera for $47.50 per share, plus up to $22.50 CVR on clinical milestones.Metsera adds four obesity drug programs, led by GLP-1 agonist MET-097i in phase II studies.The acquisition marks Pfizer's return to obesity after halting danuglipron earlier this year.Pfizer (PFE) announced a definitive agreement to acquire obesity drug developer, Metsera (MTSR) , to re-enter the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss pill, earlier this ye ...